A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Glucokinase (GK) Activator HMS5552 and Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Sinogliatin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hua Medicine
- 07 Jun 2017 Biomarkers information updated
- 16 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 10 Mar 2015 An IND application has been filed with the US FDA, according to a Hua Medicine media release.